Decreased fecal calprotectin levels in Spondyloarthritis patients colonized by Blastocystis spp.

Jacqueline Chaparro-Olaya1,7*, Liliana Morales1, Moisés David León Falla2, Paula C. Hernández2, Wilson Bautista-Molano3, Alejandro Ramos-Casallas2, Juliette de Ávila3, Juan Manuel Bello-Gualtero4, Fabián Cortés Muñoz5 & Consuelo Romero-Sánchez6

Spondyloarthritis (SpA) is a group of chronic inflammatory systemic diseases mainly characterized by inflammation in the spine and/or peripheral joints. Although a link between SpA-pathogenesis, intestinal inflammation and gut dysbiosis has been proposed, studies have been focused on bacteria-host interactions and very little has been reported regarding intestinal parasites. Here, intestinal parasitic infection of 51 SpA-patients were evaluated and compared to healthy control individuals. No significant differences in the frequency of any parasite between SpA-patients and control individuals were found. Significantly higher levels of fecal calprotectin (FCP) were found in the SpA-patients compared to the control individuals. However, FCP levels were the same when comparing SpA-patients and control individuals, both colonized by Blastocystis spp. On the other hand, when comparing Blastocystis spp. colonized and Blastocystis spp. free SpA-patients, FCP levels were significantly higher in those Blastocystis spp. free. Without ignoring the small sample size as a study limitation, the results showed that in the SpA-patients colonized by Blastocystis spp., the FCP levels were significantly lower than those in the Blastocystis spp. free group and comparable to those in the control group. These findings seem to suggest a relationship between Blastocystis spp. and intestinal inflammation in SpA-patients, but studies intended to explore that interaction specifically should be designed.

Spondyloarthritis, (SpA) is a family of chronic inflammatory joint diseases. The main symptoms experienced by SpA-patients are inflammatory back pain and/or asymmetrical arthritis. In some rare cases, uveitis or enthesitis may be the primary manifestation. According to the 2009 Assessment in Spondyloarthritis International Society (ASAS) classification1, SpA-patients can be diagnosed with axial SpA (ankylosing spondylitis [AS] is the most studied of this group) or with peripheral SpA (which includes reactive arthritis [ReA], psoriatic arthritis [PsA], arthritis associated with inflammatory bowel disease [IBD], undifferentiated SpA [uSpA] and juvenile SpA [JSpA])2. Gastrointestinal manifestations are frequent in SpA-patients and gut inflammation is one of the most important ones. The research on interaction between intestinal inflammation and arthritis was derived from demonstrating a high prevalence of ileitis or colitis in SpA-patients: 80% in JSpA, 65% in ReA, 65% in uSpA, 57% in AS and 16% in PsA3,4. Accordingly, a high risk of progression to AS has been observed in patients with chronic intestinal inflammation and diarrhea5 and intestinal inflammation is verifiable through endoscopic and histological examination in 40–60% of AS-patients6. Likewise, a higher prevalence of inflammatory bowel disease (IBD) in AS-patients has also been described, compared to healthy control individuals5,8. Although the exact pathogenic pathway by which concomitant inflammation occurs in the gut and joints is unknown, it has been

1Laboratorio de Parasitología Molecular, Vicerrectoría de Investigaciones, Universidad El Bosque, Bogotá, Colombia. 2Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque, Bogotá, Colombia. 3Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque. Clinical Immunology Group, School of Medicine, Hospital Military Central, Bogotá, Colombia. 4Rheumatology and Immunology Department & Clinical Immunology Group, School of Medicine, Hospital Military Central, Bogotá, Colombia. 5Vicerrectoría de Investigaciones, Universidad El Bosque, Bogotá, Colombia. 6Cellular and Molecular Immunology Group InmuBo, Universidad El Bosque, Rheumatology and Immunology Department & Clinical Immunology Group, School of Medicine, Hospital Military Central, Bogotá, Colombia. 7Present address: Laboratorio de Parasitológica Molecular, Instituto de Biología Molecular, Universidad de El Bosque, Edificio O. Segundo piso, Avenida Cra. 9 No, 131 A – 02, Bogotá, Colombia. *email: chaparrojacqueline@unbosque.edu.co
suggested that intestinal inflammation alters the immune system and intestinal permeability, which allows antigens and activated macrophages to enter into circulation and produce joint inflammation3,10.

On the other hand, although there is evidence of a relationship between intestinal inflammation and SpA pathogenesis, the role of the microbiome in that interaction is still unclear. In fact, there are very few reports in this regard and most of them explore the relationship between certain types of bacterial gut infections and AS. Although some studies have not found disturbances of the main bacterial groups in the fecal microflora of AS-patients (Bacteroides, Eubacterium-Clasteridium and Bifidobacterium)11, Costello et al. demonstrated a relationship between disease status and bacterial community composition when comparing AS-patients to control individuals. Therefore, the authors presented the first characterization and identification of intestinal dysbiosis in the AS microbiome12. At the same time, the association between the disease and Klebsiella pneumoniae (which was proposed initially as the main microbial trigger and/or perpetuator of AS) has been investigated exhaustively, with contradictory results13. The picture is more complex when considering that gut microbiota studies in SpA-patients have focused on bacteria-host interactions and very little has been reported regarding intestinal parasites. There are only a few known case reports that point to Blastocystis spp.14,15, Cryptocephalidium16,17, Dracunculus18, Endolimax nana19, Entamoeba hartmanni20, Entamoeba histolytica21,22, Giardia intestinalis23-24, Strongyloides stercoralis25,26,27 and Taenia saginata19,28 as causal agents of ReA. Some reports propose Toxoplasma gondii as a triggering agent of ReA19, but more recent studies suggest these findings may be coincidental27. As far as we know, there are only a few studies on intestinal parasitosis and SpA, and all of them focus on ReA: the aforementioned study on T. gondii22, another one on G. intestinalis28 and another on Giardia in a retrospective and large health insurance cohort29.

The aim of this work was to analyze intestinal parasitosis in a group of SpA-patients and to evaluate its relationship with intestinal inflammation. Because fecal calprotectin (FCP) is released during neutrophil activation30 and reflects the increased migration of these cells into the intestinal lumen and through the inflamed mucosa, FCP levels are high in patients with active inflammatory bowel diseases31. Additionally, several studies have shown this protein is elevated in SpA-patients and IBD-patients, and that it correlates well with histological inflammation detected by colonoscopy31-38. Therefore, FCP was used as a marker of inflammation.

Results

Population. Fifty-one SpA-patients and 50 control individuals were included in the study. Among the SpA-patients, 86.27% (n = 44) were AS-patients, 7.84% (n = 4) uSpA-patients and 5.89% (n = 3) PSpA-patients. Regarding clinical expression, 82.35% (n = 42) had axial involvement, 11.76% (n = 6) peripheral and 5.89% (n = 3) mixed. In all, 96.08% (n = 49) were receiving treatment, and ASDAS-CRP and ASDAS-ESR disease activity indices both showed active disease in 90.2% of the cases. The demographic and clinical characteristics of the participants are summarized in Table 1.

FCP and clinical characteristics. Elevated FCP levels (≥ 120 ng/ml) were found in 21.57% (n = 11) of the SpA-patients and 14.0% (n = 7) of the control individuals. The median FCP concentration was significantly higher in the SpA-patients compared to the control group (p = 0.0082) (Table 1). Analyzing the subgroup of SpA-patients who had elevated FCP versus the subgroup of SpA-patients with normal FCP (< 120 ng/ml), gastrointestinal symptoms were present in 80.0% of the former group and 81.82% of the latter. On the other hand, according to the limit values established for CRP (C-reactive protein) and ESR (Erythrocyte Sedimentation Rate) (< 3 mg/L and < 20 mm/h, respectively), 11.76% (n = 6) of the SpA-patients had elevated values for CRP, 31.57% (3 men and 13 women) for ESR and 7.84% (n = 4) for both. Among SpA-patients, 52.94% (n = 27) had normal values for FCP, ESR and CRP simultaneously, and none had all three markers elevated at the same time. Finally, Spearman correlation coefficients showed that FCP was positively correlated with ESR, BASDAI and ASDAS-ESR, and had no correlation with CRP, BASFI and ASDAS-CRP (Table 2).

Intestinal parasite infection. There were no significant differences in the frequency of any parasite between SpA-patients and control individuals and none of the samples were positive for helminths (Table 3. Supplementary Fig. S1). No parasitic species was exclusive to any of the groups, except Entamoeba coli, E. histolytica and the Entamoeba complex which occurred in 7.84% of the SpA-patients and 10% of the control individuals (Supplementary Table S1).

In summary, all the participants were infected with at least one of eight intestinal protists (Table 3). Because E. nana was present in 100% of the population, this parasite was not taken into account in the analyses of association with clinical characteristics. Parasites that were present in a very low proportion, or as co-infection with any other intestinal parasite different from E. nana, were also not included. Therefore, I. bütschlii, G. intestinalis, C. mesnili, Entamoeba coli, E. histolytica and the Entamoeba complex were not included in the analysis (Table 3 and Supplementary Table S1). The only parasite that met the requirements for analysis was Blastocystis spp.

Blastocystis spp. Although it was established that there was a significant difference in FCP levels between the SpA-patients and the control individuals (p = 0.0082), analysis showed no significant difference when Blastocystis spp. colonization was taken into account. To perform this analysis, individuals without Blastocystis spp.
Table 1. Demographic and clinical characteristics of SpA-patients and control subjects. SD, standard deviation. IR, interquartile range. FCP, fecal calprotectin. SpA, Spondyloarthritis. CRP, C-reactive protein. ESR, erythrocyte sedimentation rate. NSAIDs, non-steroidal anti-inflammatory agents. cDMARDs, conventional disease modifying anti-rheumatic drugs. bDMARDs, biological disease modifying anti-rheumatic drugs. (*) Z test of proportion differences. (**) Wilcoxon rank-sum test.

| Variable | SpA-patients (n = 51) | Control subjects (n = 50) | p value |
|----------|----------------------|--------------------------|---------|
| Sex (n-%) |                      |                          |         |
| Female   | 21–41.18             | 23–46.00                 | 0.6250* |
| Male     | 30–58.82             | 27–54.00                 |         |
| Age (years) Median (IR) | 43 (36–53) | 38 (29–52) | 0.0701** |
| FCP (ng/ml) Median (IR) | 53.9 (43.89–98.88) | 44.64 (41.9–56.8) | 0.0082** |
| Treatment (n-%) |                      |                          |         |
| None     | 2–3.92               |                          |         |
| NSAIDs   | 9–17.65              |                          |         |
| cDMARDs (Sulfasalazine/Methotrexate) | 5–9.80 |            |         |
| bDMARDs. Anti-IL17 (n = 4) | 35–68.63 |            |         |
| bDMARDs. Anti-TNFα (n = 31) |            |            |         |
| SpA markers |                    |                          |         |
| CRP (mg/dL) Median (IR) | 0.37 (0.15–2.23) |            |         |
| ESR (mm/h) |                      |                          |         |
| General Median (IR) | 10 (5–25) |            |         |
| Female Median (IR) | 25 (14–30) |            |         |
| Male Median (IR) | 5 (3–11) |            |         |
| BASDAI Mean (SD) | 4.58 (2.46) |            |         |
| BASDAI (n-%) |                      |                          |         |
| Without active difficulty | 24–47.06 |            |         |
| With active difficulty | 27–52.94 |            |         |
| BASFI Mean (SD) | 4.22 (2.81) |            |         |
| BASFI (n-%) |                      |                          |         |
| Without active difficulty | 25–49.02 |            |         |
| With active difficulty | 26–50.98 |            |         |
| ASDAS CRP Mean (SD) | 2.41 (0.80) |            |         |
| ASDAS CRP scores (n-%) |                    |                          |         |
| Inactive disease | 5–9.8 |            |         |
| Moderate activity | 11–21.57 |            |         |
| High activity | 30–49.02 |            |         |
| Very high disease activity | 5–9.8 |            |         |
| ASDAS-ESR Mean (SD) | 2.63 (0.98) |            |         |
| ASDAS-ESR scores (n-%) |                    |                          |         |
| Inactive disease | 5–9.8 |            |         |
| Moderate activity | 8–15.69 |            |         |
| High activity | 26–50.98 |            |         |
| Very high disease activity | 12–23.5 |            |         |
| Gastrointestinal symptoms (n-%) |                 |                          |         |
| Presence of symptoms | 38–74.51 |            |         |
| Diarrhea lasting more than 4 weeks | 25–49.02 |            |         |
| Blood in stool | 8–15.69 |            |         |
| Mucus in stool | 12–23.53 |            |         |
| Abdominal pain | 34–66.67 |            |         |
| Weight loss | 9–17.65 |            |         |
| Abdominal distention | 33–64.71 |            |         |
| Bowel movements per day. Median (IR) | 1 (1–3) |            |         |

(individuals not infected with any parasite, except E. nana) and individuals with Blastocystis spp. (those who, in addition to E. nana, had Blastocystis spp. as the only co-infecting parasite) were compared. Although a signifi-
A significant difference in FCP levels was still observed between SpA-patients and the control group in individuals without Blastocystis spp., there was no difference when individuals with Blastocystis spp. were compared (Table 4).

Additionally, when comparing median FCP concentrations among the SpA-patients, significantly lower values were observed in those colonized by Blastocystis spp. In the control group, no such difference was observed between Blastocystis spp. colonized and Blastocystis spp. free individuals (Table 5).

Among the SpA-patients colonized by Blastocystis spp. 15.38% had elevated CRP and 34.61% had elevated ESR. In the SpA-patients without Blastocystis spp., these frequencies were similar (14.28% and 35.71%, respectively). Additionally, in the SpA-patients with Blastocystis spp. versus those without Blastocystis spp., there were no significant differences in median values for CRP [0.64 mg/L (0.22–2.46) versus 0.43 mg/L (0.17–2.45) (p = 0.0842)] or ESR [10.0 mm/h (4.25–25) versus 14.5 mm/h (9.25–23.75) (p = 0.8723)]. Regarding gastrointestinal symptoms, 85.71% of the SpA-patients colonized by Blastocystis spp. and 76.92% of the SpA-patients without Blastocystis spp. reported at least one gastrointestinal symptom. None of gastrointestinal complaints could be linked to Blastocystis spp. (Supplementary Table S2).

**Table 2.** Correlations between FCP and CRP, ESR, BASDAI, BASFI and ASDAS in SpA-patients. FCP: fecal calprotectin. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate. Spearman’s correlation coefficient was calculated and the strength of correlation (Strength) was classified as poor (zero < rho < 0.3) and fair (0.3 ≤ rho < 0.6)39.

| Parasite                          | Diagnostic method | Total | SpA-patients (n = 51) | Control subjects (n = 50) | p value |
|-----------------------------------|-------------------|-------|-----------------------|---------------------------|---------|
| Chlamydia coli                    | Microscopy        | 3     | 2                     | 1                         | 0.5579* |
| Endolimax nana                    | Microscopy        | 101   | 51                    | 50                        | –       |
| Entamoeba histolytica             | PCR               | 6     | 4                     | 2                         | 0.4000* |
| Blastocystis spp.                 | Microscopy and qPCR | 73    | 34                    | 39                        | 0.2724* |
| Giardia intestinalis              | Microscopy        | 3     | 1                     | 2                         | 0.5579* |

**Table 3.** Intestinal parasites found in SpA-patients and control subjects. (1): Because *E. histolytica* cannot be morphologically differentiated from *E. dispar* and *E. moshkovskii* by microscopic examination, a PCR assay was done to identify *E. histolytica*. Microscopic examination revealed the presence of *Entamoeba* complex in three samples. The *E. histolytica* PCR was negative for these three samples, but revealed six additional infections. (*) Z test of proportion differences.

**Table 4.** Fecal calprotectin levels in *Blastocystis* spp. free and *Blastocystis* spp. colonized individuals: Comparison between SpA-patients and healthy control subjects. IR, interquartile range. (**) Group comparisons were performed using a Wilcoxon rank-sum test. Bonferroni correction was applied to account for multiple comparisons.
Table 5. Fecal calprotectin levels in SpA-patients and control subjects: Comparison between Blastocystis spp. free and Blastocystis spp. colonized individuals. IR, interquartile range. (**) Group comparisons were performed using a Wilcoxon rank-sum test. Bonferroni correction was applied to account for multiple comparisons.

|                      | Without Blastocystis spp. | With Blastocystis spp. | p value |
|----------------------|---------------------------|------------------------|---------|
| Fecal Calprotectin (ng/ml). Median (IR) |
| SpA-patients (n=40) | n=14 | 78.3 (50.75–208.36) | n=26 | 57.06 (43.5–89.03) | 0.0036** |
| Control subjects (n=37) | n=9 | 44.0 (42.0–46.7) | n=28 | 43.75 (41.0–55.0) | 0.3684** |

Discussion

In this work, clinical characteristics of 51 SpA-patients and the frequency of intestinal parasitosis in them, were evaluated. As noted in the introduction section, research on the associations between SpA and intestinal microbiome has focused mainly on an analysis of prokaryotes, while information on parasites has been limited to a few case reports of ReA.

In this study, 100% of the participants (51 SpA-patients and 50 control individuals) showed infection with some intestinal protist and none of them with helminths (Table 3). There were no significant differences in the frequency of any parasite between the SpA-patients and the control individuals, and the most prevalent parasite in both groups was *E. nana*, followed by *Blastocystis* spp.

Although there are some studies that have proposed *E. nana* as a cause of diarrhea, these findings have been debated for reasons including lack of evidence regarding co-infection with other intestinal microorganisms causing this symptomatology, and even misdiagnosis of *E. nana*. Similarly, a study that proposed *E. nana* as a cause of parasitic rheumatism also was refuted because no tests were done to diagnose the reported ReA.

We concur with the opinion that *E. nana* does not cause intestinal inflammation per se. Coupled with the fact that it was present in 100% of the participants, it meant this parasite was not taken into account in the analyses of association with demographic or clinical characteristics. It is relevant to note that there is very little research focused specifically on the study of *E. nana* and, in general, the reported prevalences correspond to findings in studies focused on other parasites or to general searches for intestinal parasitosis. In fact, a search for “Endolimax nana [title]” in PubMed (on the 15th of July 2022) identified only 15 articles and most of them are relatively old. In Colombia, high frequencies of *E. nana* colonization were reported when simultaneous diagnosis is made by direct examination and by concentration (for example, 60% in Bermúdez et al. and 77.35% in Hernández et al.). However, these were local studies on minority groups or schoolchildren from vulnerable communities. Furthermore, when comparing epidemiological data from different studies, not only the diagnostic method and the target population should be considered, but also the period when the surveillance was carried out. For example, a retrospective study in Chile involving 68.142 preschool and school children showed that *E. nana* decreased from 26.26% in 1980 to 10.14% in 2007. However, a later Chilean study in 103 students from urban and rural schools found an *E. nana* prevalence of 40.2%. A similar result (41.2%) was obtained among 119 healthy food handlers from Zulia, Venezuela. In Brazil, a study conducted in 3,245 individuals (aged 1 to 93 years) attending the FIOCruz Institute identified *E. nana* as the most common enteric parasite (6.66%). The same in 595 children and adults living in Brazilian urban slums in whom *E. nana* was detected with a prevalence of 16%.

In the United States, 2,896 patients from throughout the country were tested for intestinal parasites and *E. nana* was detected in 46 participants (1.6%). A similar prevalence was found (1.5%) in 2,604 patients from the states of Colorado, Montana, Utah, and New Mexico. In Algeria, *E. nana* was found in 233 out 2,054 children and adult patients (11.34%) in the youngest (1–10 years) to 34.04% in the group over 50 years of age. In Europe, a study in areas with poor sanitation in Slovakia analyzed 2,760 individuals aged 1 month to 88 years and revealed 16 (0.58%) positive samples for *E. nana*. Similarly, in a retrospective study in 572 Swiss children attending a hospital, *E. nana* was the second most frequent parasite (0.5%). Considering the available background on the epidemiology of *E. nana*, it is not possible to estimate the frequency of this parasite in the study population (SpA-patients and healthy adults) and to try to explain the high prevalence found.

Regarding *Blastocystis* spp., it is also difficult to compare the frequency found in this study to those in earlier reports, since studies have shown that *Blastocystis* spp. prevalence is highly dependent on the population studied and techniques employed for diagnosis. For example, a literature search on reports of *Blastocystis* spp. in Brazil between 2000 and 2020 revealed frequencies between 0.5% and 86.6% in the 52 studies ultimately included in the analysis. Similarly, a study in China from 1990 to 2019 found prevalences of *Blastocystis* spp. in a range of 0.04% to 43.26%. In the present study, the prevalence of *Blastocystis* spp. was 66.67% in the SpA-patients and 76.47% in the control individuals, which did not represent a significant difference. The high prevalence of *Blastocystis* spp. in healthy adult groups (even in industrialized countries) has already been reported, as well as its higher prevalence in control groups compared to patients with intestinal inflammation.

As for FCP, its concentration was significantly higher in the SpA-patients compared to the control individuals. Similar findings have been previously reported. Simultaneously, in the SpA-patients, a positive and significant correlation was observed between FCP/ESR, FCP/BASDAI and FCP/ASDAS-ESR, but not between FCP/CRP, FCP/BASFI or FCP/ASDAS-CRP (Table 2). No relationship was found between the level of FCP and gastrointestinal symptoms.
On the other hand, when analyzing FCP in individuals without *Blastocystis* spp., the result was the same as that found in the general population: FCP concentration was significantly higher in the SpA-patients than in the control individuals. However, when SpA-patients and control individuals, both colonized by *Blastocystis* spp. were compared, there was no difference in FCP levels (Table 4). Likewise, when comparing *Blastocystis* spp. colonized and *Blastocystis* spp.-free SpA-patients, FCP levels were significantly lower in those colonized. This difference was not observed in the control group (Table 5). This behavior of the control group differed with the findings of Nieves-Ramirez et al. who enrolled healthy individuals free of gastrointestinal disorders and measured FCP in subgroups of subjects who were positive and negative for *Blastocystis* spp. They showed that FCP levels in all the individuals were well below levels compatible with clinical inflammation, but were significantly lower in those colonized by *Blastocystis* spp. More recently, Ibrahim et al. analyzed stool samples from children and showed that colonization with *Blastocystis* spp. had no significant effect on FCP levels. In the face of contradictory evidence, we believe these findings may not be comparable due to the diverse aims and approaches of the studies and the differences in experimental designs and sociodemographic characteristics of the study populations. In addition, the existence of indirect factors that have not been contemplated and could influence these findings cannot be ruled out. Therefore, studies aimed at specifically analyzing the effect of *Blastocystis* spp. colonization on intestinal inflammation in SpA-patients are needed.

In a recent study in which rats were inoculated with *Blastocystis* cysts (isolated from feces of an asymptomatic human donor) and colitis was induced to monitor the intensity of inflammation compared to a control group, it was found that long-term colonization with *Blastocystis* spp. was associated with a more severe initial response but a more rapid recovery from colitis. Although it will have to be confirmed that these findings can be translated to humans, they suggest that long-term colonization with *Blastocystis* spp. may be a protective factor by promoting a more rapid resolution of intestinal inflammation.

With regard to ESR and CRP, no differences in the values of these parameters were observed between SpA-patients with and without *Blastocystis* spp. Similarly, Coskun et al. compared *Blastocystis* spp. colonized and *Blastocystis* spp.-free ulcerative colitis patients and found no significant differences in ESR and CRP values. In contrast, Javaherizadeh et al. reported significantly higher ESR values in individuals colonized by *Blastocystis* spp. (11.16 ± 8.67 versus 10.32 ± 5.01, p < 0.01). However, the study included subjects who went to hospitals for routine checkups and does not state or analyze the existence of any underlying disease or clinical condition. The authors also found elevated CRP values in colonized individuals more frequently (1.46%) than in non colonized individuals (0.5%), but did not report median concentration values for each group.

Finally, it is necessary to remark the potential influence of drug therapy on FCP levels. In this study, 68.63% of the SpA-patients received treatment with DMARDs (Anti IL-17 or Anti TNF-α), 17.65% with NSAIDs and 9.80% with cDMARDs (sulfasalazine or sulfasalazine and methotrexate). As for NSAIDs, their gastrointestinal toxicity has been widely reported. It is known they can increase intestinal permeability within hours of administration and trigger small bowel inflammation days later. In the long term, they can lead to a condition known as NSAID-induced enteropathy, which causes elevation of inflammatory markers such as FCP. Even so, it is unlikely these drugs contribute significantly to the etiology of inflammation in SpA, as NSAID enteropathy is not usually localized in the ileum or colon. Along the same line, a study in Spain with 33 SpA-patients found that treatment with NSAIDs did not modify FCP levels. Likewise, a study in Brazil with 85 SpA-patients and another in Croatia with 61 children who were diagnosed with SpA found that median FCP concentrations were the same between patients who received NSAIDs or DMARDs and those who did not. The foregoing leads to the assumption that the observed differences in FCP levels or parasite colonization within the SpA-patients group are unlikely to be the result of treatment. Other authors such as Klingberg et al. showed that FCP levels in AS-patients increased as the frequency of NSAID intake increased, and discontinuation of the drug for three weeks led to a drop in FCP values. However, the authors pointed out that this effect was not due solely to the use of this type of medication, since they found elevated FCP levels in 63% of the patients who did not use NSAIDs or did so only a few times a year. Similarly, these authors found significantly lower FCP values in patients receiving methotrexate and infliximab treatment, but not so in those receiving etanercept or sulfasalazine. The findings for adalimumab were conflicting. Although the number of individuals is not sufficient to make a conclusive comparison, in this study we found no difference in median FCP values between the SpA-patients receiving anti-TNF-α (n = 31), NSAIDs (n = 9) or sulfasalazine (n = 3) treatment: 49.70 ng/ml, 49.97 ng/ml and 45.65 ng/ml, respectively.

The study limitations included the small sample size and the fact that we are unable to establish whether *Blastocystis* spp. can actually influence FCP concentration in SpA-patients, or whether an unknown intestinal context promotes the presence of *Blastocystis* spp. and reduced inflammation. A study specifically focused on *Blastocystis* spp. is needed, which also takes into account the intestinal microbiome and the possible influence of therapeutic treatment.

To our knowledge, this is the first study that simultaneously analyzes the parasitic intestinal population and the clinical characteristics of SpA-patients. Without ignoring the aforementioned study limitations, the results showed that in the SpA-patients colonized by *Blastocystis* spp., the FCP levels were significantly lower than those in the *Blastocystis* spp.-free group and comparable to those in the control group. Although the data seem to suggest a relationship between *Blastocystis* spp. and intestinal inflammation in SpA-patients, studies intended to explore that interaction specifically should be designed.

**Methods**

**Study population.** A group of individuals with diagnosis of SpA (SpA-patients) and a group of healthy individuals (control) were included in the sample. Participants were enrolled between April 2019 and February 2020. The SpA-patients were subjects older than 18 and younger than 65 years of age. They were selected...
by a group of experienced rheumatologists, according to the criteria of the ASAS group\(^1\), who questioned them about the presence of gastrointestinal symptoms (diarrhea, mucus in the stool, hematochezia, increased daily bowel movements, abdominal pain or abdominal distension). SpA-patients were enrolled from two health institutions in Bogotá, Colombia (Hospital Militar Central and Clinicos IPS SAS). The control group consisted of healthy individuals residing in Bogotá, with similar age, profession and socioeconomic conditions, in whom the presence of joint and gastrointestinal symptoms was ruled out. Young women or patients with a history of infection in the last month, autoimmune disease, neoplasia, immunodeficiency, chronic pancreatitis, liver disease or diabetes were not included. Participants who had taken any antibiotic or antiparasitic in the last three (3) months, or who were receiving any dose of systemic steroid at the time of inclusion in the study were also not included. The rheumatologic involvement of each patient was assessed using the following clinical indices: BASFI, BASDAI, ASDAS-CRP and ASDAS-ESR\(^{71,72}\). A stool sample was collected from each participant to diagnose intestinal parasitosis and to measure FCP. For participants who had a positive diagnosis for intestinal parasitosis, treatment was prescribed by a physician according to the infecting species. Additionally, a blood sample was collected from each patient to measure CRP and ESR.

**Ethics declarations.** This study was conducted in accordance with the principles outlined in the Declaration of Helsinki and guidelines established by the Ministerio de Salud y Protección Social de Colombia for research involving human subjects. SpA-patients and control individuals made a voluntary decision about participating in the study and signed an informed consent for collection/use of data and samples. Ethics Committee of Hospital Militar Central in Bogotá, Colombia (records number 09 of May 5, 2017, and 09 of June 1, 2018. Code: 2017-023) approved this research.

**FCP, CRP and ESR measures.** Quantitative measurement of FCP level was performed by ELISA based methods using KAPEPKT849 kit (DIAsource ImmunoAssays S.A. Louvain-la-Neuve, Belgium). Chemiluminescence immunoassay Immulite 1000 (Siemens Healthineers. Erlangen, Germany) and Westergren sedimentation rate testing were used on blood samples to measure CRP and ESR, respectively.

**Microscopic detection of intestinal parasites.** Stool samples were analyzed by microscopic examination using three setups: wet mount (0.9% saline solution and 4% lugol), concentration with the Mini-Parasep SF system (DiaSys. Wokingham, UK) and Kato-Katz (Sterlitech. Washington, USA). Two bacteriologists with certified clinical experience read each mount.

**Molecular detection of E. histolytica, G. intestinalis and Blastocystis spp.** In addition to microscopy-based parasite identification, the presence of *E. histolytica* was assessed by PCR, while the presence of *G. intestinalis* and *Blastocystis* spp. was confirmed by quantitative PCR (qPCR).

First, DNA from ~200 μl of concentrated stool samples was extracted using the QIAamp DNA Stool Mini Kit (Qiagen. Germantown, USA). Then, *Enterobacteriaceae* 16S rRNA gene-specific primers and a TaqMan® probe (synthesized by Macrogen. Seoul, Korea) (Supplementary Table S3) were used to confirm successful DNA extraction by qPCR\(^{73}\). *Enteroctococcus faecalis* strain ATCC 29212 was used as positive control. The qPCR reactions were performed with TaqMan® Fast Advanced Master Mix (BioRad. Hercules, USA) and run on a CFX96 Touch real-time PCR system (BioRad. Hercules, USA).

Because *E. histolytica* cannot be morphologically differentiated from *E. dispar* and *E. moshkovskii* through microscopic examination, a semi-nested PCR protocol to amplify the 18S rRNA gene was done to identify *E. histolytica*\(^{74,75}\). Both PCR reactions were carried out in a mix containing 0.2 mM dNTPs, 2 mM MgCl2, 0.5 μM of each primer (synthesized by Macrogen. Seoul, Korea) (Supplementary Table S3) and DNA GoTaq® Flexi DNA Polymerase (Promega. Madison, USA). Reactions were performed on a T100 PCR thermal cycler (BioRad. Hercules, USA) as follows: 3 min at 94 °C and 35 cycles of 1 min at 94 °C, 1 min at 55 °C, and 1 min at 72 °C, with a final step of 7 min at 72 °C. As template, 3 μl of each DNA extraction were used in the first PCR and then 2 μl of the PCR products from the first step were used as templates for the second step. A plasmid containing the product of the first amplification was produced and used as positive control. The identity of the construct was confirmed by sequencing (Macrogen-Seoul, Korea).

*Giardia intestinalis* and *Blastocystis* spp. were identified by qPCR using the primers and TaqMan probes reported by Mejia et al.\(^{76}\) and Stensvold et al.\(^{76}\), respectively (synthesized by Macrogen. Seoul, Korea) (Supplementary Table S3). Reactions were performed individually for each parasite with 2 μl of DNA extraction as template and TaqMan® Fast Advanced Master Mix (BioRad. Hercules, USA). Programs were run on a CFX96 Touch Real-Time PCR System (BioRad. Hercules, USA) as in Mejia et al.\(^{76}\) and Stensvold et al.\(^{76}\). DNA of *G. intestinalis* (strain WB) and *Blastocystis* spp. (strain BT1) were used as templates in the qPCR reactions and the obtained products were cloned (vector pJET1.2blunt.Thermo Scientific™. Waltham, USA), sequenced (Macrogen. Seoul, Korea) and used as templates in calibration curves (dilutions between 10,000 fg/μL to 0.1 fg/μL).

**Statistical Analysis.** Descriptive statistics, including mean, median, standard deviation (SD), and interquartile ranges, were used to characterize the study population according to the assumption of normality, as evaluated using the Shapiro–Wilk test. Group comparisons were performed using a mean-difference Z test to continuous variables conforming to a normal distribution; otherwise, a Wilcoxon rank-sum test was applied to other continuous variables. Dichotomic qualitative variables were compared between two groups using a Z test of proportion differences. Correlations between variables were evaluated by Spearman’s correlation due to a non-normal distribution in those variables. When it was appropriate, Bonferroni correction was applied to
account for multiple comparisons. A p value < 0.05 was considered statistically significant. Statistical analyses were performed using Stata V.12.1.

Data availability
The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request, and may be requested via email to romeromaria@unbosque.edu.co.

Received: 21 September 2021; Accepted: 9 August 2022
Published online: 23 September 2022

References
1. Sieper, J. et al. The Assessment of Spondyloarthritis International Society (ASAS) handbook: A guide to assess spondyloarthritis. *Ann. Rheum. Dis.* 68, 44. https://doi.org/10.1136/ard.2008.104018 (2009).
2. Zeidler, H. & Amor, B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. *Ann. Rheum. Dis.* 70, 1–3 (2011).
3. Mielants, H., Veys, E. M., Cuvelier, C. & De Vos, M. Course of gut inflammation in spondyloarthropathies and therapeutic consequences. *Baillieres. Clin. Rheumatol.* 10, 147–164 (1996).
4. Smale, S., Natt, R. S., Orchard, T. R., Russell, A. S. & Bjarnason, I. Inflammatory bowel disease and spondyloarthropathy. *Arthritis. Rheum.* 44, 2728–2736 (2001).
5. De Vos, M., Mielants, H., Cuvelier, C., Elevaert, A. & Veys, E. Long-term evolution of gut inflammation in patients with spondyloarthritis. *Gastroenterology* 110, 6. https://doi.org/10.1053/gast.1996.v110.pm8964936 (1996).
6. Karreman, M. C., Luime, J. J., Hazes, J. M. W. & Weel, A. E. A. M. The prevalence and incidence of axial and peripheral spondyloarthritis in inflammatory bowel disease: a systematic review and meta-analysis. *J. Crohns Colitis.* 11, 631–642 (2017).
7. Kontny, E. & Dmowska-Chalaba, J. Spondyloarthritis patients with and without intestinal symptoms-searching for discriminating features. *Curr. Opin. Rheumatol.* 30, 160–169 (2018).
8. Tejera, B., Grados, D., Martinez-Morillo, M. & Roure, S. Arthritis reactiva por Blastocystis hominis. *Reumatol. Clin.* 25, 2162–2176 (2019).
9. Mielants, H., Veys, E. M., Cuvelier, C. & De Vos, M. Ileocolonoscopic findings in seronegative spondyloarthropathies. *Br. J. Rheumatol.* 27, 95–105 (1988).
10. Specia, S. & Dubuaqoy, L. Chronic bowel inflammation and inflammatory joint disease: Pathophysiology. *Jt. Bone Spine* 84, 417–420 (2017).
11. Stebbings, S. et al. Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. *Rheumatology (Oxford)* 41, 1395–1401 (2002).
12. Costello, M. E. et al. Brief Report: Intestinal dysbiosis in ankylosing spondylitis. *Arthritis. Rheumatol.* 67, 686–691 (2015).
13. Zhang, L. et al. The association of HLA-B27 and Klebsiella pneumoniae in ankylosing spondylitis: a systematic review. *Microb. Pathog.* 117, 49–54 (2018).
14. Tejera, B., Grados, D., Martinez-Morillo, M. & Roure, S. Arthritis reactiva por Blastocystis hominis [Reactive arthritis caused by Blastocystis hominis]. *Reumatol. Clin.* 8, 50–51 (2012).
15. Alamlih, L., Abufaied, M. & Al-Allaf, A. W. An unusual cause of reactive arthritis with urticarial: A case report. *Qatar Med. J.* 2, 25. https://doi.org/10.5339/qmj.2020.25 (2020).
16. Hay, E. M., Winfield, J. & McKendrick, M. W. Reactive arthritis associated with Cryptosporidium enteritis. *Br. Med. J. (Clin. Res. Ed.)* 295, 248. https://doi.org/10.1136/bmj.295.6592.248 (1987).
17. Shepherd, R. C., Small, P. J. & Sinha, G. P. Reactive arthritis complicating cryptosporidial infection. *Arch. Dis. Child.* 64, 743–744 (1989).
18. McGill, P. E. Rheumatic syndromes associated with parasites. *Baillieres Clin. Rheumatol.* 9, 201–213 (1995).
19. Inman, R. D. Arthritis and enteritis—an interface of protein manifestation. *Arch. Med. Res.* 14, 406–410 (1987).
20. Schirmer, M. et al. *Entamoeba hartmanni*: A new causative agent in the pathogenesis of reactive arthritis? *Rheumatol. Int.* 18, 37–38 (1998).
21. Than-Saw et al. Isolation of *Entamoeba histolytica* from arthritic knee joint. *Trop Geogr. Med.* 44, 355–358 (1992).
22. Woo, P. & Panayi, G. S. Reactive arthritis due to infestation with *Giardia lamblia*. *J. Rheumatol.* 11, 719 (1984).
23. Shaw, R. A. & Stevens, M. B. The reactive arthritis of *giardiasis*. A case report. *JAMA* 258, 2734–2735 (1987).
24. González-Gay, M. A., Cereijo, M. J., Agüero, J. J. & Sánchez-Andrade, A. Arthritis reactiva a *Giardia lamblia* [Arthritis reactive to *Giardia lamblia*]. *Med. Clin. (Barc.).* 26, 359 (1992).
25. Bocanegra, T. S., Espinoza, L. R., Bridgeford, P. H., Vasey, F. R. & Germán, B. F. Reactive arthritis induced by parasitic infestation. *Ann. Intern. Med.* 94, 207–209 (1981).
26. Richter, J. et al. Arthritis associated with *Strongyloides stercoralis* infection in HLA B2–positive African. *Parasitol. Res.* 99, 706–707 (2006).
27. Sert, M., Ozbek, S., Paydas, S. & Yaman, A. Is there any relationship between *Toxoplasma* infection and reactive arthritis?. *J. Postgrad. Med.* 53, 14–16 (2007).
28. Cantey, P. T. et al. Study of nonoutbreak giardiasis: novel findings and implications for research. *Am. J. Med.* 124, 1175. https://doi.org/10.1016/j.amjmed.2011.06.012 (2011).
29. Painter, J. E., Collier, S. A. & Gargano, J. W. Association between *Giardia* and arthritis or joint pain in a large health insurance cohort: Could it be reactive arthritis?. *Epidemiol. Infect.* 145, 471–477 (2017).
30. Juhne, B. et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. *Mol. Pathol.* 50, 113–123 (1997).
31. Simioni, J. et al. *Fecal Calprotectin*, gut Inflammation and spondyloarthritis. *Arch. Med. Res.* 40, 41–46 (2019).
32. Bjarnason, I. et al. Subclinical intestinal inflammation and sarcoidosis changes in relatives of patients with ankylosing spondylitis. *Gastroenterology* 125, 1598–1605 (2003).
33. Konikoff, M. & Denison, L. A. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. *Inflamm. Bowel Dis.* 12, 524–534 (2006).
34. Klingberg, E., Carlsten, H., Hilme, E., Hedberg, M. & Forsblad-d’Elia, H. Calprotectin in ankylosing spondylitis-frequently elevated in feces, but normal in serum. *Scand. J. Gastroenterol.* 47, 435–444 (2012).
35. Matzikis, F. G. et al. Markers of intestinal inflammation in patients with ankylosing spondylitis: A pilot study. *Arthritis. Res. Ther.* 14, 261. https://doi.org/10.1186/ar4106 (2012).
36. Klingberg, E. et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. *Arthritis. Res. Ther.* 19, 21. https://doi.org/10.1186/s13075-017-1223-2 (2017).
37. Moreno, M. J., Moreno, M. J. & Linares, L. E. Relationship between fecal calprotectin, anti- Saccharomyces cerevisiae antibodies and other markers of disease activity in patients with spondylarthropathy. *Reumatol. Clin. (Engl. Ed.).* 15, 360–362 (2019).
40. Poulsen, C. S. & Stensvold, C. R. Systematic review on Endolimax nana: a less well studied intestinal ameba. Trop. Parasitol. 6, 8–29 (2016).
41. Burnstein, S. L. & Liakos, S. Parasitic rheumatism presenting as rheumatoid arthritis. J. Rheumatol. 10, 514–515 (1983).
42. Bermúdez, A., Flórez, O., Bolaños, M. V., Medina, J. J. & Salcedo-Cifuentes, M. Enteroparasitismo, higiene y saneamiento ambiental en menores de seis comunidades indígenas. Cali-Colombia [Enteroparasitism, hygiene and environmental sanitation in under-aged from six indigenous communities. Cali-Colombia]. Rev. Salud Pública. 15, 11–13 (2013).
43. Hernández, P. C. et al. Intestinal parasitic infections and associated factors in children of three rural schools in Colombia. A cross-sectional study. PLoS One. 14, e0218681; https://doi.org/10.1371/journal.pone.0218681 (2019).
44. Vidal, S., Tolotia, L. & Cancino, B. Evolución de la prevalencia de enteroparasitosis en la ciudad de Talca, Región del Maule, Chile. Rev. Chilena Infectol. 27, 336–340 (2010).
45. Freites, A., Colmenares, D., Pérez, M., García, M. & Díaz de Suárez, O. Infección por Cryptosporidium sp y otros parásitos intestinales en manipuladores de alimentos del estado Zulia, Venezuela. Invest. Clin. 50, 13–21 (2009).
46. Faria, C. P. et al. Geospatial distribution of intestinal parasitic infections in Rio de Janeiro (Brazil) and its association with social determinants. PLoS Negl. Trop. Dis. 11, e0005445 (2017).
47. Ignacio, C. F. et al. Socioenvironmental conditions and parasitic infections in Brazilian urban slums: A cross-sectional study. Rev. Inst. Med. Trop. Sao Paulo. 7, 59 (2017).
48. Amin, O. M. Seasonal prevalence of intestinal parasites in the United States during 2000. Am. J. Trop. Med. Hyg. 66, 799–803 (2002).
49. Church, C., Neill, A. & Schotthoefer, A. M. Intestinal infections in humans in the Rocky Mountain region, United States. J. Parasitol. 96, 194–196 (2010).
50. Belkessa, S. et al. Prevalence and Clinical Manifestations of Giardia intestinalis and Other Intestinal Parasites in Children and Adults in Algeria. Am. J. Trop. Med. Hyg. 18, 910–916 (2021).
51. Graczyk, T. K. et al. The association of Blastocystis hominis and Endolimax nana with diarrheal heal in Vanzanto school-age children. Parasitol. Res. 98, 38–43 (2005).
52. Sarker, B., Hosseini, G., Motazedian, M. H., Fararouei, M. & Moshfie, A. Prevalence and risk factors of intestinal protozoan infections: A population-based study in rural areas of Boyer-Ahmad district, Northwestern Iran. BMC Infect. Dis. 16, 703 (2016).
53. Dudlová, A. et al. Prevalence of non-pathogenic types of gastrointestinal protozoa in population in Slovakia and their potential importance in the aspect of public health. Acta Parasitol. 63, 819–825 (2018).
54. Légeret, C., Rüttimann, C., Fankhauser, H. & Köhler, H. Parasitic infections in Swiss children: Are we overtesting? BMC Gastroenterol. 21, 39 (2021).
55. De Melo, G. B., Bosqui, L. R., Da Costa, I. N., De Paula, F. M. & Gryschek, R. Current status of research regarding Blastocystis sp., an enigmatic protist, in Brazil. Clinics. 76, e2489. https://doi.org/10.6061/clinics/2021/e2489 (2021).
56. Ping, C. Q., Hu, Z. H., Chen, J. H., Ai, L. & Tian, L. G. Epidemiology of Blastocystis infection from 1990 to 2019 in China. Infect Dis Poverty. 9, 168. https://doi.org/10.1186/s40429-020-00779-z (2020).
57. Scanlan, P. D. The microbial eukaryote Blastocystis is a prevalent and diverse member of the healthy human gut microbiota. FEMS Microbiol. Ecol. 90, 326–330 (2014).
58. Lhotska, Z. et al. A study on the prevalence and subtype diversity of the intestinal protist Blastocystis sp. In a gut-healthy human population in the Czech Republic. Front. Cell Infect. Microbiol. 9, 544335; https://doi.org/10.3389/fcimb.2020.544335 (2020).
59. Petersen, A. M. et al. Active ulcerative colitis associated with low prevalence of Blastocystis and Dientamoeba fragilis infection. Scand. J. Gastroenterol. 48, 638–639 (2013).
60. Andersen, L. O., Bonde, I., Nielsen, H. B. & Stensvold, C. R. A retrospective metagenomics approach to studying Blastocystis. FEMS Microbiol. Ecol. 91, 7. https://doi.org/10.1093/femsec/fov072 (2015).
61. Tito, R. Y. et al. Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota. Gut 68, 1180–1189 (2019).
62. Nieves-Ramirez, M. E. et al. Asymptomatic intestinal colonization with protist Blastocystis is strongly associated with distinct microbiome ecological patterns. mSystems. 3, e00017-18; https://doi.org/10.1128/mSystems.00017-18 (2018).
63. Ibrahim, H. S., Salem, A. I., Ahmed, N. M. A. E. R. & El-Taweel, H. A. Pre-and post-treatment evaluation of Intestinal Inflammation in Giardia and Blastocystis infected children: a community-based study. J. Parasit. Dis. https://doi.org/10.21203/rs.3.rs-308755/v1 (2021).
64. Billy, V. et al. Blastocystis colonization alters the gut microbiome and, in some cases, promotes faster recovery from induced colitis. Front Microbiol. 12, 641483. https://doi.org/10.3389/fmicb.2021.641483 (2021).
65. Coskun, A. et al. Blastocystis in ulcerative colitis patients: genetic diversity and analysis of laboratory findings. Asian Pac. J. Trop. Med. 9, 916–919 (2016).
66. Javaherizadeh, H., Khademvatan, S., Soltani, S., Torabizadeh, M. & Yousefi, E. Distribution of haematological indices among adults in Algeria. Prz Gastroenterol. 9, 38–42 (2014).
67. Maiden, L., Thijodleifsson, B., Theodors, A., Gonzalez, J. & Bjaransson, I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128, 1172–1178 (2005).
68. Bjaransson, L., Hayllar, J., MacPherson, A. J. & Russell, A. S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104, 1832–1847 (1993).
69. Lamot, L. et al. The increased levels of fecal calprotectin in children with active enthesitis related arthritis and MRI signs of sacroiliitis: The results of a single center cross-sectional exploratory study in juvenile idiopathic arthritis patients. Front. Med. 8, 650619. https://doi.org/10.3389/fmed.2021.650619 (2021).
70. Garrett, S. et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 21, 2286–2291 (1994).
71. Lukas, C. et al. Assessment of SpoDyloroArthritis International Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 68. 18–24 (2009).
72. Menu, E. et al. Evaluation of two DNA extraction methods for the PCR-based detection of eukaryotic enteric pathogens in fecal samples. BMC Res Notes. 11, 206. https://doi.org/10.1186/s13104-018-3300-2 (2018).
73. Hanza, Z., Petntrit, S., Muangthim, M., Leelayova, S. & Chavalitswixin, Z. Petntrit, P. Differential detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii by a single-round PCR assay. J. Clin. Microbiol. 44, 3196–3200 (2006).
74. Mejia, R. et al. A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am. J. Trop. Med. Hyg. 88, 1041–1047 (2013).
75. Stensvold, C. R., Ahmed, U. N., Andersen, L. O. & Nielsen HV. Development and evaluation of a genus-specific, probe-based, internal-process-controlled real-time PCR assay for sensitive and specific detection of Blastocystis spp. J Clin Microbiol. 50, 1847–1851 (2012).
Acknowledgements
This work was supported by Universidad El Bosque (Project PCI-2018-10091), Ministerio de Ciencia Tecnología e Innovación (Grant 13087757442-2018), Hospital Militar Central (Project 2017-023), IPS Clinics, Gastroadvanced IPS, Investigación y Biomedicina de Chihuahua and Fundación Instituto de Reumatología Fernando Chalem. Funding organizations had no role in study design, data analysis or preparation of the manuscript.

Author contributions
J.C.O., J.D.A. and P.C.H. designed the study. C.R.S. and P.C.H. participated in acquisition of funding. C.R.S., JMBG and WBM diagnosed and enrolled the patients. C.R.S. enrolled the control subjects. A.R.C., C.R.S., J.C.O., L.M., M.D.L.F. and W.B.M. contributed to data collection. A.R.C., C.R.S., J.M.B.G. and W.B.M. contributed to sample collection. L.M. and M.D.L.F. performed diagnosis of intestinal parasites. F.C.M., J.C.O., L.M. and P.C.H. performed data analysis and interpretation. J.C.O. wrote the manuscript. C.R.S., J.D.A., LM, P.C.H. and W.B.M. reviewed the manuscript. All the authors approved the version to be published.

Competing interests
The authors declare no competing interests.

Competing interests.
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-18308-3.

Correspondence and requests for materials should be addressed to J.C.-O.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022